{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451563965
| IUPAC_name = {6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate
| image = Givinostat structure.svg
| alt =  

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A, B1, B2, B3, C, D, X -->
| pregnancy_US = <!-- A, B, C, D, X -->
| pregnancy_category = —
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = IND<!-- OTC, Rx-only, Schedule I, II, III, IV, V -->
| legal_status = 
| legal_EU_comment = [[Orphan drug|Orphan status]] for [[juvenile idiopathic arthritis|sJIA]]
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 7490
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 497833-27-9
| ATCvet =  
| ATC_prefix = none
| ATC_suffix =   
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5P60F84FBH
|  PubChem = 9804992
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 7980752
|  smiles = O=C(OCc2cc1ccc(cc1cc2)CN(CC)CC)Nc3ccc(cc3)C(=O)NO
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = YALNUENQHAQXEA-UHFFFAOYSA-N

<!--Chemical data-->
| C=24 | H=27 | N=3 | O=4 
| molecular_weight = 421.489 g/mol
}}
'''Givinostat''' ([[International Nonproprietary Name|INN]]<ref>[[World Health Organization]] (2010). [http://www.who.int/medicines/publications/druginformation/innlists/RL63.pdf "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 63".] ''WHO Drug Information'' '''24''' (1): 58–9.</ref>) or '''gavinostat''' (originally '''ITF2357''') is a [[histone deacetylase inhibitor]] with potential [[anti-inflammatory]], [[anti-angiogenic]], and [[antineoplastic]] activities.<ref>[[National Cancer Institute]] (2010). [http://www.cancer.gov/drugdictionary/?CdrID=560751 "Gavinostat".] ''NCI Cancer Dictionary''. U.S. National Institutes of Health. Retrieved 2010-09-15.</ref> It is a [[hydroxamate]] used in the form of its [[hydrochloride]].

Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas),<ref>{{cite web|url=http://clinicaltrials.gov/ct2/results?term=ITF2357|publisher=ClinicalTrials.gov|title=Search results for ITF2357}}</ref> and has been granted [[orphan drug]] designation in the [[European Union]] for the treatment of [[juvenile idiopathic arthritis|systemic juvenile idiopathic arthritis]]<ref name=JIA>{{cite web|author=Committee for Orphan Medicinal Products|date=23 February 2010|url=http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/02/WC500074739.pdf|title=Public summary of opinion on orphan designation: Givinostat for the treatment of systemic-onset juvenile idiopathic arthritis|publisher=[[European Medicines Agency]]|accessdate=2010-09-15}}</ref> and [[polycythaemia vera]].<ref name=PV>{{cite web|author=Committee for Orphan Medicinal Products|date=3 March 2010|url=http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2010/03/WC500075167.pdf|title=Public summary of opinion on orphan designation: Givinostat for the treatment of polycythaemia vera|publisher=European Medicines Agency}}</ref>

ITF2357 was discovered at [[:it:Italfarmaco|Italfarmaco]] of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005.<ref>[http://www.wipo.int/pctdb/en/fetch.jsp?SEARCH_IA=EP1997002407 WO patent application 1997/043251], "Compounds with anti-inflammatory and immunosuppressive activities", published 1997-11-20, assigned to Italfarmaco S.p.A.</ref><ref name=Leoni>Leoni F, Fossati G. (2005). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1449516 "The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo".] ''Molecular Medicine'' '''11''': 1. {{doi|10.2119/2006-00005.Dinarello}}. {{PMID|16557334}}.</ref>

==Adverse effects==
In clinical trials of givinostat as a [[salvage therapy]] for advanced [[Hodgkin's lymphoma]], the most common [[adverse drug reaction|adverse reactions]] were [[fatigue (medical)|fatigue]] (seen in 50% of participants), mild diarrhea or abdominal pain (40% of participants), moderate [[thrombocytopenia]] (decreased [[platelet]] counts, seen in one third of patients), and mild [[leukopenia]] (a decrease in [[white blood cell]] levels, seen in 30% of patients). One-fifth of patients experienced [[QT interval#Due to adverse drug reactions|prolongation]] of the [[QT interval]], a measure of electrical conduction in the heart, severe enough to warrant temporary suspension of treatment.<ref name=Tan>Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010). [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2827364 "Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents".] ''Journal of Hematology & Oncology'' '''3''': 5. {{doi|10.1186/1756-8722-3-5}}. {{PMID|20132536}}. Review.</ref>

==Mechanism of action==
Givinostat inhibits class I and class II [[histone deacetylase]]s (HDACs) and several pro-inflammatory [[cytokine]]s. This reduces expression of [[tumour necrosis factor]] (TNF), [[interleukin 1]]α and β, and [[interleukin 6]].<ref name=Leoni/>

It also has activity against cells expressing ''JAK2(V617F)'', a mutated form of the [[janus kinase 2]] (JAK2) enzyme that is implicated in the pathophysiology of many [[myeloproliferative disease]]s, including polycythaemia vera.<ref>Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A (2009). [http://www.medscape.com/viewarticle/589735 "Treatment options for essential thrombocythemia and polycythemia vera."] ''Expert Review of Hematology'' '''2''' (1): 41–55. {{doi|10.1586/17474086.2.1.41}}. Review.</ref><ref>Guerini V, Barbui V, Spinelli O, et al. (April 2008). "The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)". ''Leukemia'' '''22''' (4): 740–7. {{doi|10.1038/sj.leu.2405049}}. {{PMID|18079739}}.</ref> In patients with polycythaemia, the reduction of mutant JAK2 concentrations by givinostat is believed to slow down the abnormal growth of [[erythrocyte]]s and ameliorate the symptoms of the disease.<ref name=PV/>

==References==
{{reflist}}

==Further reading==
* {{cite web|publisher=Orphanet|first=C|last=Job-Deslandre|title=Idiopathic juvenile-onset systemic arthritis|url=http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=85414|at=Orphan number: ORPHA85414 |date=January 2007}}
* {{cite web|last1=Amaru Calzada|first1=Ariel|last2=Todoerti|first2=Katia|last3=Donadoni|first3=Luca|last4=Pellicioli|first4=Anna|last5=Tuana|first5=Giacomo|last6=Gatta|first6=Raffaella|last7=Neri|first7=Antonino|last8=Finazzi|first8=Guido|last9=Mantovani|first9=Roberto|last10=Rambaldi|first10=Alessandro|last11=Introna|first11=Martino|last12=Lombardi|first12=Luigia|last13=Golay|first13=Josée|title=The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells|url=https://www.ncbi.nlm.nih.gov/pubmed/22579713|website=Experimental Hematology|pages=634–645.e10|doi=10.1016/j.exphem.2012.04.007|date=August 2012}}

{{HDAC inhibitors}}

[[Category:Hydroxamic acids]]
[[Category:Histone deacetylase inhibitors]]
[[Category:Orphan drugs]]
[[Category:Experimental drugs]]